Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential

Nanomedicine

Volumn 5, Issue 2, 2010, Pages 181-192

  Kuesters, Geoffrey M ^a   Campbell, Robert B ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Anti angiogenesis; Bevacizumab; Cancer therapy; Cationic liposomes; Drug delivery; Endothelial cells; Nanotechnology; Pancreatic cancer; Vasculature targeting

Indexed keywords

BEVACIZUMAB; CATION; LIPOSOME; PEGYLATED CATIONIC LIPOSOME; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL LINE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG TARGETING; DRUG UPTAKE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN SECRETION; TUMOR VASCULARIZATION; ZETA POTENTIAL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CATIONS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; LIPOSOMES; NEOPLASMS; POLYETHYLENE GLYCOLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952531028     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.105     Document Type: Article

References (44)

1. Philip PA: Targeted therapies for pancreatic cancer. Gastrointest. Cancer Res. 2(Suppl. 4), S16-S19 (2008).
2. Shaib YH, Davila JA, El-Serag HB: The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol. Ther. 24(1), 87-94 (2006).
3. Denekamp J: Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br. J. Cancer 45(1), 136-139 (1982).
4. Vincent S, DePace D, Finkelstein S: Distribution of anionic sites on the capillary endothelium in an experimental brain tumor model. Microcirc Endothelium Lymphatics 4(1), 45-67 (1988).
5. Campbell RB, Fukumura D, Brown EB et al.: Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62(23), 6831-6836 (2002).
6. Thurston G, McLean J W, Rizen M et al.: Cationic liposomes target angiogenic endothelial cells in tumors and chronic infammation in mice. J. Clin. Invest. 101(7), 1401-1413 (1998).
7. Campbell RB, Ying B, Kuesters GM, Hemphill R: Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J. Pharm. Sci. 98(2), 411-429 (2009).
8. Schuch G: EndoTAG-1. MediGene. Curr. Opin. Investig. Drugs 6(12), 1259-1265 (2005).
9. Campbell RB: Tumor physiology and delivery of nanopharmaceuticals. Anticancer Agents Med. Chem. 6(6), 503-512 (2006).
10. Conejo JR, Kleeff J, Koliopanos A et al.: Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int. J. Cancer 88(1), 12-20 (2000).
11. Kaji T, Yamamoto C, Oh-i M et al.: The vascular endothelial growth factor VEGF165 induces perlecan synthesis via VEGF receptor-2 in cultured human brain microvascular endothelial cells. Biochim. Biophys. Acta 1760(9), 1465-1474 (2006).
12. Dabbas S, Kaushik RR, Dandamudi S, Kuesters GM, Campbell RB: Importance of the liposomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human primary and transformed endothelial cells. Endothelium 15(4), 189-201 (2008).
13. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066(1), 29-36 (1991).
14. Dandamudi S, Campbell RB: Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature. Biochim. Biophys. Acta 1768(3), 427-438 (2007).
15. Immordino ML, Dosio F, Cattel L: Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 1(3), 297-315 (2006).
16. Dandamudi S, Campbell RB: The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 28(31), 4673-4683 (2007).
17. Folkman J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
18. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333(26), 1757-1763 (1995).
19. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2(10), 795-803 (2002).
20. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25(4), 581-611 (2004). (Pubitemid 39099316)
21. Pellet-Many C, Frankel P, Jia H, Zachary I: Neuropilins: structure, function and role in disease. Biochem. J. 411(2), 211-226 (2008).
22. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3(5), 391-400 (2004).
23. Cohen MH, Gootenberg J, Keegan P, Pazdur R: FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as frst-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6), 713-718 (2007).
24. Cohen MH, Gootenberg J, Keegan P, Pazdur R: FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12(3), 356-361 (2007).
25. Gerber HP, Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65(3), 671-680 (2005).
26. Shih T, Lindley C: Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther. 28(11), 1779-1802 (2006).
27. Sachdev JC, Jahanzeb M: Evolution of bevacizumab-based therapy in the management of breast cancer. Clin. Breast Cancer 8(5), 402-410 (2008).
28. Scheer MG, Stollman TH, Boerman OC et al.: Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: lack of correlation with VEGF-A expression. Eur. J. Cancer 44(13), 1835-1840 (2008).
29. Stollman TH, Scheer MG, Franssen GM et al.: Tumor accumulation of radiolabeled bevacizumab due to targeting of cell-and matrix-associated VEGF-A isoforms. Cancer Biother. Radiopharm. 24(2), 195-200 (2009).
30. Stollman TH, Scheer MG, Leenders WP et al.: Specifc imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int. J. Cancer 122(10), 2310-2314 (2008).
31. Nagengast WB, de Vries EG, Hospers GA et al.: In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med. 48(8), 1313-1319 (2007).
32. Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M: Targetability of novel immunoliposomes modifed with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta 1234(1), 74-80 (1995).
33. Pan X, Wu G, Yang W, Barth RF, Tjarks W, Lee RJ: Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug. Chem. 18(1), 101-108 (2007).
34. Park J W, Hong K, Kirpotin DB et al.: Anti-HER2 immunoliposomes: enhanced effcacy attributable to targeted delivery. Clin. Cancer Res. 8(4), 1172-1181 (2002).
35. Schnyder A, Krahenbuhl S, Torok M, Drewe J, Huwyler J: Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem. J. 377(Pt 1), 61-67 (2004).
36. Kirpotin D, Park JW, Hong K et al.: Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36(1), 66-75 (1997).
37. Ades EW, Candal FJ, Swerlick RA et al.: HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 99(6), 683-690 (1992).
38. Skehan P, Storeng R, Scudiero D et al.: New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl Cancer Inst. 82(13), 1107-1112 (1990).
39. Kalra AV, Campbell RB: Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. Pharm. Res. 23(12), 2809-2817 (2006).
40. Itakura J, Ishiwata T, Friess H et al.: Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res. 3(8), 1309-1316 (1997).
41. Niedergethmann M, Hildenbrand R, Wostbrock B et al.: High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25(2), 122-129 (2002).
42. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88(10), 2239-2245 (2000).
43. Sun HC, Qiu ZJ, Liu J et al.: Expression of hypoxia-inducible factor-1a and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int. J. Oncol. 30(6), 1359-1367 (2007).
44. Bockhorn M, Tsuzuki Y, Xu L, Frilling A, Broelsch CE, Fukumura D: Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin. Cancer Res. 9(11), 4221-4226 (2003).